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Macrophage accumulation characterizes the formation of atherosclerotic plaques. Recent work in Nature
Immunology (van Gils et al., 2012) demonstrates that the neuroimmune guidance cue netrin-1 can retain
macrophages in atherosclerotic lesions, thus promoting atherosclerosis.Though previously regarded as a choles-
terol storage disease, most now agree
that inflammation characterizes athero-
sclerosis. In the 1970s and 1980s, athero-
sclerosis researchers focused primarily
on the plaque’s smooth muscle cell
(SMC) component. These cells generate
the extracellular matrix that reinforces
the plaque’s fibrous skeleton, conferring
resistance to rupture, a frequent cause
of thrombosis. Work conducted during
this period elucidated important signals
that stimulate SMC proliferation and
migration. In recent decades, the study
of atherogenesis has broadened to en-
compass inflammatory cells, now re-
cognized as key participants in lesion
formation and complication. Virtually all
leukocyte classes shape the course
of disease in varied and consequential
ways, but the mononuclear phagocytes—
monocytes, macrophages, and dendritic
cells—constitute themajority of inflamma-
tory cells that congregate in atheroscle-
rotic lesions (Hansson and Libby, 2006).
The study by van Gils et al. (2012) casts
the spotlight on a relatively neglected
aspect of the economy of mononuclear
phagocytes in atherosclerosis: the pros-
pect that active signals prevent accumu-
lated macrophages from emigrating from
the lesion.
Atherosclerotic lesions produce clini-
cally important thrombotic complications
most frequently when physical disruption
brings blood into contact with the
‘‘necrotic core’’—the lesion’s inner com-
partment and repository of dead mono-
nuclear phagocytes that accumulated
as lipid-laden macrophages, or foam
cells. Mononuclear phagocytes disturb
SMC function and endothelial-dependent
vasodilatation. Central to the inflam-
matory cascade, mononuclear phago-
cytes secrete cytokines and proteinasesthat exacerbate inflammation, degrade
the plaque’s extracellular matrix, impair
the lesions’ mechanical stability, and
heighten susceptibility to thrombotic
complications. Altogether, mononuclear
phagocytes are critical to the formation
of atheromata and participate in the
most dramatic and morbid clinical mani-
festations of disease.
Over the last two decades, many
laboratories have investigated the mech-
anisms mediating the recruitment of
monocytes—the precursors of lesional
macrophages—to nascent atheroscle-
rotic plaques (Weber and Noels, 2011;
Ley et al., 2011). A combination of
in vitro and in vivo studies using human
tissues and experimental animals identi-
fied adhesive ligands and chemokine
receptor pairs as gatekeepers that dictate
the entry of monocytes into the artery
wall. Monocytes belonging to various
subsets accumulate during lesion in-
itiation and long-term lesional growth
(Swirski et al., 2007; Tacke et al., 2007).
If atherosclerotic lesions indeed grow
through rapid monocyte accumulation,
can we curb atherosclerosis by inter-
fering with monocyte/macrophage flux?
Recent studies support this possibility.
In atherosclerotic mice, lesion regression
occurs either by reduced monocyte
accumulation (Potteaux et al., 2011) or
by increased departure of macrophages
from lesions via CCR7 and its ligands
CCL19 and CCL21 (Llodra´ et al., 2004;
Feig et al., 2010). Achieving the ‘‘right
balance’’ between monocyte entry and
macrophage exit may therefore represent
a promising therapeutic strategy.
The study by van Gils et al. pro-
vides considerable insight into how this
‘‘right balance’’ can be accomplished.
The authors focus on the role of netrin-1,
a guidance molecule that mediatesCell Metabolism 15axonal chemoattraction and chemore-
pulsion and inhibits leukocyte migra-
tion (Cirulli and Yebra, 2007). van Gils
et al. first show that, in murine models
of atherosclerosis (LDL-receptor-defi-
cient [Ldlr/] and apolipoprotein-defi-
cient [apoE/] mice), macrophage foam
cells abundantly express netrin-1 and
one of its receptors, UNC5b. On the basis
of this observation, they test the hypoth-
esis that netrin-1 and UNC5b retain
macrophages in plaques. In vitro, perito-
neal macrophages treated with oxidized
LDL (oxLDL) augment Ntn1 and Unc5b
mRNA via the scavenger receptor
CD36, whereas the addition of netrin-1 to
RAW264.7 cells and peritoneal macro-
phages prevents chemokine-induced
actin-1 polymerization, interrupts the
Rac1 signaling pathway, and inhibits
chemotaxis. Netrin-1, van Gils et al.
conclude, blocks the directed migration
of macrophages (Figure 1).
SMCs express neogenin, a classical
receptor for netrin-1. van Gils et al.
show that netrin-1 chemoattracts human
coronary artery SMCs in a neogenin-
dependent manner. Unlike macrophages,
medial SMCs and SMCs that have mi-
grated to the intima express neogenin
at high levels, indicating that netrin-1
modulates the migration of coronary
artery SMCs and macrophages through
distinct mechanisms.
To investigate the role of netrin-1 in vivo,
van Gils et al. generate Ldlr/ chimeric
mice that lack netrin-1 expression on
hematopoietic cells. In response to a
high-fat and high-cholesterol Western
diet, these mice develop smaller, less
complex lesions, with fewer macro-
phages and SMCs. To conclude that
netrin-1 indeed prevents macrophage
exit, van Gils et al. utilize a bead method
for tracking monocyte accumulation and, February 8, 2012 ª2012 Elsevier Inc. 135
Figure 1. Proposed Model for Netrin-1 Acting as a Retention Signal
for Macrophages in Atheromata
The new study by van Gils et al. shows that netrin-1, acting via the receptor
UNC5b, retains macrophages in atherosclerotic lesions. The sequence of
steps is as follows: (1) A monocyte enters the growing atheromata via chemo-
kine receptors such as CCL2/CCR2; (2) monocyte-derived macrophages
ingest oxLDL via CD36, which results in the production and (3) release of ne-
trin-1; (4) netrin-1 binds to the UNC5b receptor onmacrophages and neogenin
on smoothmuscle cells; (5) macrophages become unresponsive to chemokine
signals and remain in the growing atheromata; (6) Smoothmuscle cells migrate
toward the netrin-1 gradient and accumulate in the intima; (7) netrin-1-deficient
macrophages readily exit atherosclerotic lesions, resulting in smaller lesions.
Mf (macrophage); SMC, smooth muscle cell.
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Previewsmacrophage exit (Tacke
et al., 2007; Potteaux et al.,
2011). Netrin-1-deficient pla-
ques have a 40% decrease
in the number of beads
14 days after labeling.
Netrin-1, therefore, appears
to provide a retention signal
to macrophages.
While the study by van Gils
et al. is elegant, some key
questions remain. First, we
should seek to determine
what component of oxLDL, a
highly heterogeneous and var-
iable mixture, triggers CD36-
induced netrin-1 expression.
Characterizing the nature of
mononuclear phagocytes that
exit atherosclerotic plaques,
and determining whether
netrin-1 retainsvariousmacro-
phage populations in other in-
flammatory contexts, will also
be important. Although van
Gils et al. have focused largely
on netrin-1-mediated macro-
phage retention, the observa-
tion that netrin-1 beckons
SMCs in vitro raises the profile
of this molecule as an impor-
tant orchestrator of cellular
accumulation.Targeting adhesion molecules and
chemokines that guide monocyte entry
could yield therapeutic benefit, but is
subject to limitation if certain aspects
of monocyte accumulation are athero-
protective, or if certain subsets accumu-
late by yet unknown mechanisms. The136 Cell Metabolism 15, February 8, 2012 ª2identification of netrin-1 as a retention
factor for lesional macrophages re-
presents an alternative therapeutic ap-
proach. The novel pathway and the
concepts explored by van Gils et al. not
only increase our understanding of the
mechanisms underlying atherosclerosis012 Elsevier Inc.progression, but may also
have therapeutic potential.REFERENCES
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